JOP20220110A1 - ناهضات مستقبل npy2 - Google Patents

ناهضات مستقبل npy2

Info

Publication number
JOP20220110A1
JOP20220110A1 JOP/2022/0110A JOP20220110A JOP20220110A1 JO P20220110 A1 JOP20220110 A1 JO P20220110A1 JO P20220110 A JOP20220110 A JO P20220110A JO P20220110 A1 JOP20220110 A1 JO P20220110A1
Authority
JO
Jordan
Prior art keywords
receptor agonists
analogues
npy2 receptor
relates
npy2
Prior art date
Application number
JOP/2022/0110A
Other languages
English (en)
Inventor
Stefan Peters
Albert Brennauer
S?Ren Ljungberg Pedersen
Charlotte Stahl Madsen
Peter Wilhelm Haebel
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of JOP20220110A1 publication Critical patent/JOP20220110A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2271—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

يتعلق الاختراع بنظائر PYY تحتوي على ألانين عند الموضع 4، ليسين عند الموضع 7، QRY كنهاية طرفية C ومجموعة إطالة عمر النصف. تكون النظائر من الاختراع قابلة للذوبان بحوالي درجة حموضة 6 و7. يتعلق الاختراع أيضًا بالتركيبات الصيدلانية التي تشتمل على نظائر PYY، وبالاستخدام الطبي للنظائر.
JOP/2022/0110A 2019-11-11 2020-11-09 ناهضات مستقبل npy2 JOP20220110A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19208394 2019-11-11
PCT/EP2020/081513 WO2021094259A1 (en) 2019-11-11 2020-11-09 Npy2 receptor agonists

Publications (1)

Publication Number Publication Date
JOP20220110A1 true JOP20220110A1 (ar) 2023-01-30

Family

ID=68531488

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0110A JOP20220110A1 (ar) 2019-11-11 2020-11-09 ناهضات مستقبل npy2

Country Status (18)

Country Link
US (2) US20210139548A1 (ar)
EP (1) EP4058047A1 (ar)
JP (1) JP2023500895A (ar)
KR (1) KR20220100925A (ar)
CN (1) CN114641303A (ar)
AR (1) AR120440A1 (ar)
AU (1) AU2020384729A1 (ar)
CA (1) CA3156452A1 (ar)
CL (1) CL2022001227A1 (ar)
CO (1) CO2022006046A2 (ar)
CR (1) CR20220206A (ar)
EC (1) ECSP22037660A (ar)
IL (1) IL292601A (ar)
JO (1) JOP20220110A1 (ar)
MX (1) MX2022005661A (ar)
PE (1) PE20221168A1 (ar)
TW (1) TW202134263A (ar)
WO (1) WO2021094259A1 (ar)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230045088A (ko) * 2020-08-07 2023-04-04 베링거 인겔하임 인터내셔날 게엠베하 가용성 npy2 수용체 작용제
US20240091318A1 (en) 2022-08-18 2024-03-21 Boehringer Ingelheim International Gmbh Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525495A (ja) 2004-02-11 2007-09-06 アミリン・ファーマシューティカルズ，インコーポレイテッド 選択可能な特性を有するハイブリッドポリペプチド
BRPI0518559A2 (pt) 2004-12-13 2008-11-25 Amylin Pharmaceuticals Inc motivos da famÍlia do polipetÍdeo pancreÁtico, polipeptÍdeos e mÉtodos compreendendo os mesmos
AU2008216265B2 (en) 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
WO2008152403A1 (en) 2007-06-15 2008-12-18 Zealand Pharma A/S Glucagon analogues
CN101939022A (zh) 2007-11-14 2011-01-05 安米林药品公司 治疗肥胖以及肥胖相关疾病和病症的方法
WO2010070252A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
UA104605C2 (uk) 2008-12-15 2014-02-25 Зіленд Фарма А/С Аналоги глюкагону
CN102282166B (zh) 2008-12-15 2015-04-01 西兰制药公司 胰高血糖素类似物
KR101593406B1 (ko) 2008-12-15 2016-02-12 질랜드 파마 에이/에스 글루카곤 유사체
PL2454282T3 (pl) 2009-07-13 2015-08-31 Zealand Pharma As Acylowane analogi glukagonu
EP2477643A1 (en) 2009-09-18 2012-07-25 Novo Nordisk A/S Long-acting y2 receptor agonists
US20130096055A1 (en) 2009-11-13 2013-04-18 Novo Nordisk A/S Long-acting y2 receptor agonists
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
JP6023048B2 (ja) 2010-06-24 2016-11-09 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
PL2718316T3 (pl) 2011-06-10 2020-06-29 Novo Nordisk A/S Polipeptydy
KR20140114845A (ko) 2011-12-23 2014-09-29 질랜드 파마 에이/에스 글루카곤 유사체
KR102184241B1 (ko) 2012-05-03 2020-12-01 질랜드 파마 에이/에스 Ｇｉｐ-ｇｌｐ-1 이원 작용제 화합물 및 방법
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
ES2732291T3 (es) 2013-05-02 2019-11-21 Glaxosmithkline Ip Dev Ltd Péptidos terapéuticos
AR097701A1 (es) 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
EP3057984B1 (en) 2013-10-17 2018-07-11 Zealand Pharma A/S Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
TR201902516T4 (tr) 2013-11-06 2019-03-21 Zealand Pharma As Glukagon-glp-1-gıp üçlü agonist bileşikleri.
MX2016006049A (es) 2013-11-14 2016-08-12 Keybioscience Ag Mimeticos de calcitonina para tratar enfermedades y trastornos.
RS59026B1 (sr) * 2013-11-15 2019-08-30 Novo Nordisk As Selektivna pyy jedinjenja i njihova upotreba
JP6769984B2 (ja) 2015-03-18 2020-10-14 ジーランド ファーマ アクティーゼルスカブ アミリン類似体
MX2017012864A (es) 2015-04-16 2018-06-12 Zealand Pharma As Analogo acilado del glucagon.
TWI694082B (zh) 2015-06-12 2020-05-21 丹麥商諾佛 儂迪克股份有限公司 選擇性ｐｙｙ化合物及其用途
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
HRP20220995T1 (hr) 2015-12-31 2022-11-11 Hanmi Pharm. Co., Ltd. Trostruki aktivator koji aktivira glukagonski, glp-1 i gip receptore
TWI784968B (zh) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 澱粉素類似物
JOP20190097A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv الجلوبولينات المناعية واستخداماتها
AR110300A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip
AR110301A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
TWI749381B (zh) 2018-11-01 2021-12-11 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法

Also Published As

Publication number Publication date
AU2020384729A1 (en) 2022-04-14
PE20221168A1 (es) 2022-07-25
KR20220100925A (ko) 2022-07-18
CO2022006046A2 (es) 2022-05-20
CN114641303A (zh) 2022-06-17
EP4058047A1 (en) 2022-09-21
WO2021094259A1 (en) 2021-05-20
US20210139548A1 (en) 2021-05-13
US20230340039A1 (en) 2023-10-26
AR120440A1 (es) 2022-02-16
CL2022001227A1 (es) 2023-02-03
CA3156452A1 (en) 2021-05-20
ECSP22037660A (es) 2022-06-30
MX2022005661A (es) 2022-09-07
IL292601A (en) 2022-07-01
TW202134263A (zh) 2021-09-16
JP2023500895A (ja) 2023-01-11
CR20220206A (es) 2022-06-16

Similar Documents

Publication Publication Date Title
EA202192588A1 (ru) Фармацевтическая композиция, включающая вариант ph20 гиалуронидазы человека, и лекарственное средство для подкожного введения
CR20230074A (es) Agonistas del receptor npy2 solubles
PH12019550241A1 (en) Mic-1 compounds and uses thereof
MY187047A (en) Selective pyy compounds and uses thereof
MX2018014023A (es) Compuestos de citocina inhibidora de macrofagos 1 (mic-1) y uso de estos.
MX2022005661A (es) Agonistas del receptor npy2.
NZ743487A (en) Controlled-release cnp agonists with increased nep stability
MX369818B (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
NZ743488A (en) Controlled-release cnp agonists with low initial npr-b activity
NZ743489A (en) Controlled-release cnp agonists with low npr-c binding
PH12020551018A1 (en) Oral delivery of glp-1 peptide analogs
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
MX2021013743A (es) Subunidad s1 modificada de la proteina de espicula de coronavirus.
MX2022001719A (es) Formulaciones de conjugados de benzazepina y usos de las mismas.
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
PH12020551659A1 (en) Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
WO2020109526A3 (en) Oxyntomodulin peptide analog formulations
MX2022004014A (es) Composicion liofilizada que contiene 2-((s)-2-acetamido-3-(1h-indo l-3-il)propanamido)-6-diazo-5-oxohexanoato de (s)-isopropilo para administracion intravenosa y su uso.
EA202192475A1 (ru) Способ получения стабильных пептидных составов
BR112022006297A2 (pt) Agonistas de receptor de npy2
CR20220046A (es) Composiciones farmacéuticas para péptidos co-agonistas de glucagón y glp-1
RS20170169A1 (sr) Poboljšana rekonstituisana kompozicija sufraktanta koja sadrži analoge sufraktanta proteina b (sp-b) i surfaktanta proteina c (sp-c)
GR1008804B (el) Συνθεσεις για ιατρικη χρηση οι οποιες περιλαμβανουν υαλουρονικο οξυ ή αλατα αυτου, αμινοξεα, βιταμινες, ανοργανα αλατα και αλλα συστατικα